| Jaramia Matthew Jehn, | |
|
1200 Oakleaf Way Ste B, Altoona, WI 54720-2245 | |
| (715) 839-9266 | |
| Not Available |
| Full Name | Jaramia Matthew Jehn |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 7 Years |
| Location | 1200 Oakleaf Way Ste B, Altoona, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225566276 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 13786-024 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwoods Sport And Hand Inc | 9032399118 | 19 |
News Archive
"I'm going to do more sport in the new year." Hardly any resolution is made more frequently than this one after the calorie-filled Christmas holidays - and hardly one that is broken as frequently. A team headed by Prof. Wolfgang Schlicht from the Institute for Sport and Movement Science at the University of Stuttgart are investigating behaviour techniques in the framework of the project "PREVIEW" with which the physical activity behaviour can be changed in the long term. T
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.
AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.
› Verified 6 days ago
| Provider Name | Northwoods Sport & Hand Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1609966407 PECOS PAC ID: 9032399118 Enrollment ID: O20110311000809 |
News Archive
"I'm going to do more sport in the new year." Hardly any resolution is made more frequently than this one after the calorie-filled Christmas holidays - and hardly one that is broken as frequently. A team headed by Prof. Wolfgang Schlicht from the Institute for Sport and Movement Science at the University of Stuttgart are investigating behaviour techniques in the framework of the project "PREVIEW" with which the physical activity behaviour can be changed in the long term. T
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.
AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jaramia Matthew Jehn, 1200 Oakleaf Way Ste B, Altoona, WI 54720-2245 Ph: () - | Jaramia Matthew Jehn, 1200 Oakleaf Way Ste B, Altoona, WI 54720-2245 Ph: (715) 839-9266 |
News Archive
"I'm going to do more sport in the new year." Hardly any resolution is made more frequently than this one after the calorie-filled Christmas holidays - and hardly one that is broken as frequently. A team headed by Prof. Wolfgang Schlicht from the Institute for Sport and Movement Science at the University of Stuttgart are investigating behaviour techniques in the framework of the project "PREVIEW" with which the physical activity behaviour can be changed in the long term. T
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.
AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.
› Verified 6 days ago
Tj Nereng, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1200 Oakleaf Way, Suite B, Altoona, WI 54720 Phone: 715-839-9266 Fax: 715-839-8761 | |
Ryan Stearns, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1200 Oakleaf Way Ste B, Altoona, WI 54720 Phone: 715-839-9266 Fax: 715-839-8761 | |
Terry Plomedahl, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1200 N. 10th St. West, Altoona, WI 54720 Phone: 715-839-9266 | |
Eric Martin Kauffmann, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2512 New Pine Dr, Altoona, WI 54720 Phone: 715-833-0400 | |
Kari Ruth King, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3085 Meadowlark Ln, Altoona, WI 54720 Phone: 715-717-6700 | |
Carie Lynn Massey, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1200 Oakleaf Way Ste B, Altoona, WI 54720 Phone: 715-839-9266 Fax: 715-839-8761 |